This therapeutic concept proposes a microglial modulation strategy targeting individuals with TREM2 risk variants that predispose to Alzheimer's and other neurodegenerative diseases. By preventing microglial priming and the associated neurotoxic phenotype, this approach aims to preserve brain immune homeostasis before pathological accumulation triggers irreversible damage.
- TREM2 variants alter microglial function: TREM2 R47H, R62H, and other variants reduce microglial phagocytic capacity and increase risk of late-onset AD 2-4x
- Microglial priming precedes pathology: Individuals with TREM2 risk variants show altered microglial responses to amyloid even before plaque formation
- Prodromal neuroinflammation: Elevated CSF YKL-40 and IL-6 are detectable in pre-symptomatic TREM2 variant carriers
- TREM2 agonism is being actively investigated: Antibody-based TREM2 agonists are in clinical trials; prophylactic use could prevent priming
flowchart TD
subgraph Risk_Stratification
A["TREM 2 Genotyping"] --> B["TREM2 Risk Variant Status"]
B --> C["Neuroinflammation Biomarkers<br/>YKL-40, IL-6, TNF-α"]
C --> D["Microglial Priming Score"]
end
subgraph Intervention["Intervention"]
D --> E["TREM2 Agonist or Modulator<br/>Low-Dose Prophylactic"]
E --> F["Prevent Microglial Dysfunction<br/>Maintain Phagocytic Capacity"]
F --> G["Reduce Neurotoxic ROI Production<br/>Preserve Neuronal Health"]
G --> H["Block Pathological Amplification<br/>Limit Amyloid/Tau Spread"]
end
subgraph Monitoring["Monitoring"]
C --> I["Biomarker Tracking<br/>YKL-40, TREM2, neurofilament"]
I --> J["Dose Adjustment<br/>Every 12 months"]
end
| Risk Category |
Genetic Profile |
Age Range |
Recommended Protocol |
| High Risk |
TREM2 R47H/R47H |
45-60 |
TREM2 agonist prophylaxis |
| Moderate Risk |
TREM2 R47H Heterozygous |
50-65 |
Low-dose modulator + monitoring |
| Elevated Risk |
TREM2 Variant + Family History |
50-70 |
Biomarker surveillance + lifestyle |
- Epidemiology: Epidemiology of Neurodegenerative Diseases documents TREM2 as a major AD risk gene
- Biomarker studies: Blood-Based Biomarkers can track microglial activation in pre-symptomatic individuals
- Clinical trials: TREM2-targeting antibodies are in various trial phases for AD treatment
- Genetic counseling: TREM2 testing requires appropriate pre/post-test counseling
- Baseline biomarkers: Measure YKL-40, TREM2, and established AD biomarkers before treatment
- Risk-benefit analysis: weigh prophylactic treatment against potential immune suppression
- Combination potential: May synergize with APOE4 lipid modulation for comprehensive prevention